Ex vivo activation and expansion of human T cells using biocompatible substrates with tunable rigidity
- Summary
- Autologous T cells are currently being investigated for use in adoptive immunotherapy to treat cancer and infectious diseases. Existing methods to culture, expand, and activate T cells utilize ligands immobilized on stiff surfaces. However, the mechanical properties of culture surfaces influence cell adhesion, proliferation, and differentiation, and may have eventual downstream effects on T cell activity. This technology describes a culture system for the ex vivo expansion of human T cells that utilizes a biocompatible substrate with tunable rigidity. With further development, this system may mimic the cells' native microenvironment, leading to robust T cell activation ex vivo.
- Technology Benefits
- Biocompatible substrate mimics in vivo microenvironmentEnhances T cell proliferation compared to conventional stiff substratesProduces more cells with a central memory-like phenotypeCan be used for both research and clinical applicationsPatent Information:Patent Pending (WO/2013/036585)Tech Ventures Reference: IR 2941
- Technology Application
- T cell activation for research applicationsT cell activation ex vivo for autologous implantationCancer immunotherapyAutoimmune disease therapy Treatment of chronic infections
- Detailed Technology Description
- None
- *Abstract
-
None
- *Inquiry
- Richard NguyenColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
- *IR
- 2941
- *Principal Investigator
-
- *Publications
- Shen K, Milone MC, Dustin ML, Kam LC. "Nanoengineering of immune cell function" Mater Res Soc Symp Proc. 2009 Jan 1;1209.O'Connor RS, Hao X, Shen K, Bashour K, Akimova T, Hancock WW, Kam LC, Milone MC. "Substrate rigidity regulates human T cell activation and proliferation" J Immunol. 2012 Aug 1;189(3):1330-9.
- Country/Region
- USA
For more information, please click Here
